Myriad Genetics, Inc. — Form 8-K Summary
Business context and reporting period: This Form 8-K concerns an executive separation, not quarterly or annual operating results. The report identifies October 6, 2026 as the event date; it was signed on October 9, 2026.
Separation terms and financial effects
- Former Chief Commercial Officer Brian Donnelly left the position effective September 16, 2026; his employment ended at close of business on September 21, 2026.
- Under a Separation Agreement dated October 6, effective October 14, 2026 unless revoked beforehand, Mr. Donnelly is to receive a lump-sum severance payment of $1,322,294.
- Time-based equity awards scheduled to vest by September 21, 2028 are accelerated, subject to the agreement’s provisions for annual vesting installments. Outstanding performance-based awards may vest to the extent earned if their performance conditions are met by that date, with vesting limited to amounts scheduled within the two-year period.
- The consideration is provided under Mr. Donnelly’s Severance and Change of Control Agreement and is conditioned, among other things, on restrictive covenants and a release of claims.
Financial metrics and comparison
The filing provides no revenue, profit, cash flow, margins, debt, liquidity, guidance, or comparable-period financial results. It does not quantify the accounting expense or value of the equity awards associated with the separation.
Outlook, risks, and unusual items
The separation payment and equity treatment are the material compensation items disclosed. The filing does not discuss broader business outlook or operating risks. The agreement’s effectiveness depends on Mr. Donnelly not revoking it before October 14, 2026.
Key facts for investors to verify
- Review Exhibit 10.1 for the complete separation, release, and restrictive-covenant terms.
- Confirm whether the agreement became effective and whether any revocation occurred.
- Check subsequent disclosures for the recognized expense and cash-payment timing, and for the value and vesting outcomes of the accelerated or performance-based equity awards.